ACTYM THERAPEUTICS INC has a total of 16 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology and pharmaceuticals are GUANGDONG FIRST CONDOR BIOTECHNOLOGY CO LTD, CHAMELEON BIOSCIENCES INC and U S MEDICAL RES INST OF INFECT.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 2 | |
#4 | Australia | 1 | |
#5 | EPO (European Patent Office) | 1 | |
#6 | Israel | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Skoble Justin | 13 |
#2 | Glickman Laura Hix | 10 |
#3 | Thanos Christopher D | 10 |
#4 | Iannello Alexandre Charles Michel | 6 |
#5 | Glickman Laura | 5 |
#6 | Thanos Christopher | 5 |
#7 | Iannello Alexandre | 3 |
#8 | Kehoe Haixing | 2 |
Publication | Filing date | Title |
---|---|---|
US2020270613A1 | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment | |
WO2020176809A1 | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment | |
US2020071702A1 | Engineered immunostimulatory bacterial strains and uses thereof | |
WO2020014543A2 | Engineered immunostimulatory bacterial strains and uses thereof | |
CA3069523A1 | Engineered immunostimulatory bacterial strains and uses thereof |